| Old Articles: <Older 8311-8320 Newer> |
|---|
 |
Chemistry World
May 2012 |
Biotech's bravura performer Bibiana Campos Seijo talks to scientist, philanthropist and serial entrepreneur Chris Evans, who is credited with having helped create the UK biotechnology industry.   |
CIO
April 30, 2012
Stephanie Overby |
Can Watson, IBM's Supercomputer, Cure Cancer? WellPoint and Cedars-Sinai are putting IBM's supercomputer Watson to the test in pilots targeting cancer treatment and improved EMRs. |
Chemistry World
April 26, 2012
Sarah Houlton |
AstraZeneca seeks to refill dry pipeline with gout drug AstraZeneca is to acquire US-based Ardea Biosciences in a deal worth $1.26 billion. Its lead product, lesinurad, moved into Phase III trials at the end of last year for the management of patients suffering from gout. |
Pharmaceutical Executive
April 1, 2012 |
Leading from the South India's most prominent scientist sets a new agenda for pharma in emerging markets. |
Pharmaceutical Executive
April 1, 2012 |
HBA Woman of the Year 2012 Progressions is a narrative about the commercial renewal that comes from embracing diversity, and there is no better symbol for that message than the Progressions series creator, Global Pharmaceutical Sector Leader Carolyn Buck-Luce. |
Pharmaceutical Executive
April 1, 2012 |
Ad Stars The campaigns chosen as this year's Pharm Exec Ad Stars include a diverse mix of clients, health conditions, and media channels. |
Pharmaceutical Executive
April 1, 2012
Jill Wechsler |
Shortages and Sunshine Disclosure rules the day, as industry confronts demands to report supply problems, results of clinical trials, and payment to doctors. |
Pharmaceutical Executive
April 1, 2012
Feam & Lagus |
Providing Access Now While regulatory frameworks and medical practices differ between countries, many patients still need early access to new drugs. Industry can help. |
Pharmaceutical Executive
April 1, 2012
Ben Comer |
Divided Kingdom What does a Scottish vote for independence mean for Big Pharma investment and healthcare funding and delivery in the UK? |
Pharmaceutical Executive
April 1, 2012
Jim Bedford |
Navigating M&A Complexities Technical diligence is necessary to identify subsidiary connections. These must be cleverly unraveled and re-established to ensure successful carve-outs. |
| <Older 8311-8320 Newer> Return to current articles. |
